BDBM160490 US10093663, Example 30-3::US9682968, Example-30-2::US9682968, Example-30-3

SMILES COc1cc(C)c2[nH]ccc2c1CN1CC(O)CCC1c1ccc(cc1)C(O)=O

InChI Key InChIKey=BQRDGRCUTGUVKK-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 160490   

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160490(US9682968, Example-30-3 | US9682968, Example-30-2 ...)
Affinity DataIC50: 1.30nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160490(US9682968, Example-30-3 | US9682968, Example-30-2 ...)
Affinity DataIC50: 1.30nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160490(US9682968, Example-30-3 | US9682968, Example-30-2 ...)
Affinity DataIC50: 8.20nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160490(US9682968, Example-30-3 | US9682968, Example-30-2 ...)
Affinity DataIC50: 8.20nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160490(US9682968, Example-30-3 | US9682968, Example-30-2 ...)
Affinity DataIC50: 1.30E+3nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160490(US9682968, Example-30-3 | US9682968, Example-30-2 ...)
Affinity DataIC50: 1.30E+3nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160490(US9682968, Example-30-3 | US9682968, Example-30-2 ...)
Affinity DataIC50: 8.20E+3nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160490(US9682968, Example-30-3 | US9682968, Example-30-2 ...)
Affinity DataIC50: 8.20E+3nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent